Introduction
============

The past decade has witnessed a remarkable increase in access to human immunodeficiency virus (HIV) prevention modalities and lifesaving antiretroviral therapy (ART) in resource-limited settings.[@b1-hiv-10-103] This has led to notable declines in HIV incidence and HIV-related morbidity and mortality.[@b2-hiv-10-103] In Kenya, the number of people living with HIV (PLHIV) receiving ART increased a 100-fold between 2003 and 2013.[@b3-hiv-10-103],[@b4-hiv-10-103] By 2015, more than 800,000 adults aged 15 years and above, and over 70,000 children aged 0--14 years were receiving ART.[@b5-hiv-10-103] Annual acquired immunodeficiency syndrome (AIDS)-related deaths decreased by 65% between 2003 and 2013.[@b6-hiv-10-103]

In May 2014, the Joint United Nations Programme on HIV/AIDS announced ambitious new targets to have 90% of all PLHIV knowing their status, 90% of those diagnosed with HIV receiving effective ART, and 90% of those receiving ART achieving viral suppression, by the year 2020.[@b7-hiv-10-103] To meet these targets, HIV programs must identify and address challenges through lessons learnt over the last decade and a half of the HIV/AIDS response in resource-scarce settings. For instance, the median CD4 of those initiating ART has only modestly increased.[@b8-hiv-10-103] Patients starting ART at low CD4 cell counts have poorer treatment outcomes, including the risk of early mortality.[@b9-hiv-10-103] Additionally, studies from ART programs in sub-Saharan Africa (SSA) report that a third of patients on ART are lost to care by 36 months, with most attrition occurring within the first year.[@b10-hiv-10-103]

Establishing temporal trends and identifying factors associated with adverse treatment outcomes in diverse settings are key to improving long-term effectiveness of ART programs in low- and middle-income countries.[@b11-hiv-10-103] Data on temporal trends and treatment outcomes from a large HIV treatment site in rural Kenya demonstrated increased rates of retention in care.[@b12-hiv-10-103] Although the urban environment presents unique challenges and opportunities in HIV management, there is a paucity of data on temporal trends from this setting. Besides, little has been published on this topic within the context of a large, urban, referral setting in Kenya. In view of this data gap, we sought to determine trends in demographic and clinical characteristics of adult HIV-infected ART cohorts over a 12-year period at a large urban referral HIV clinic in Nairobi, Kenya. We further described how these characteristics influence attrition.

Methods
=======

Study setting and design
------------------------

This was a retrospective cohort analysis of data, which were routinely collected during and prior to the implementation of the Partnership for Advanced Care and Treatment -- Centres of Excellence (PACT-CoE) program. PACT-CoE was a US President's Emergency Plan for AIDS Relief-funded project implemented at the ambulatory HIV Comprehensive Care Centre (CCC) of the Kenyatta National Hospital (KNH) from 2010 to 2015. KNH is Kenya's largest national teaching and referral hospital. PACT-CoE's principal aim was to build capacity and scope for sustainable HIV preventive and treatment services. Patients diagnosed with HIV access the CCC from several sources, including the on-site client- and provider-initiated testing and counseling services. Care at the CCC is provided by a team of primary and specialist providers. Outpatient HIV care is provided at no cost to patients, and encompasses ART as well as treatment of, and prophylaxis against, select opportunistic infections (OIs). Free laboratory tests provided include HIV-specific investigations (CD4 T cell count and HIV RNA/DNA assays), OI screening for tuberculosis (TB) and cryptococcus, and, where indicated, additional tests such as hemogram, lipid profile, liver and renal function tests. In-country ART initiation policy guidelines based on CD4 cell count thresholds have evolved during the follow-up period, starting with CD4 ≤200 cells/mm^3^ in 2002, and increasing to CD4 ≤250, CD4 ≤350, and CD4 ≤500 cells/mm^3^ in 2007, 2010, and 2014, respectively.

HIV care and treatment consisted of a standard minimum package of care that includes evidence-based interventions and ART. Currently, the recommended first-line ART comprises tenofovir (TDF), lamivudine, and efavirenz (EFV).[@b13-hiv-10-103] Zidovudine and nevirapine are alternative nucleoside and non-nucleoside reverse transcriptase inhibitors for those unable to tolerate TDF and EFV, respectively.

Ethical consideration
---------------------

Approval for the study was obtained from the KNH/University of Nairobi Ethics and Research Committee and the US Centers for Disease Control and Prevention, Associate Director for Science. The requirement for individual informed consent was waived by the committee, as the research involved no more than minimal risk; the waiver would not adversely affect the rights and welfare of the subjects; and it would be impracticable to conduct the research without the waiver.

Selection and description of participants
-----------------------------------------

All patients ≥15 years who started ART between January 1, 2004, and September 30, 2015, were included in the analysis. Exclusion criteria were 1) patients missing the main outcome or explanatory variables of interest, such as sex, age/date of birth; 2) non-ART naïve patients -- transferred to the clinic on ART; 3) starting ART before January 1, 2004, or after September 30, 2015; and 4) aged \<15 years at ART start.

Data management and analysis
----------------------------

### Data extraction

Data were extracted using an in-built data mining functionality of an electronic medical records (EMR) system designed for HIV care and treatment and exported to Microsoft Access for analysis in SAS.

### Variable measurements

Key outcome variables that were extracted included post-ART initiation treatment status outcomes: 1) attrition (died or lost to follow-up \[LTFU\]); 2) retention on ART; and 3) transfer out of the facility. The main outcome variable of interest was attrition. This was defined as those who died or were LTFU (having no contact with the facility for at least 6 months). Retention was defined as those who were active on ART at the end of the follow-up period. Key explanatory variables included year of ART start (categorized into six groups: 2004--2006, 2007--2008, 2009--2010, 2011--2012, 2013--2014, and 2015), demographic characteristics such as sex, age at ART start (categorized into five age groups: 15--19, 20--24, 25--29, 30--54, and 55 years and older), marital status, and residence (urban/rural). Clinical characteristics included CD4 cell count (categorized into six groups: 0--50, 51--100, 101--250, 251--350, 351--499, and ≥500 cells/µL), World Health Organization (WHO) clinical stage (categorized into two: stages 1 and 2, stages 3 and 4), and OIs at ART start. Nondocumentation has previously been associated with poor outcomes among patients with HIV/AIDS.[@b14-hiv-10-103] To assess for the role of missing data on covariates we created a "not documented" category for marital status, residence, care entry point, HIV diagnosis date, disease stage, and CD4 count.

### Quality assurance

Extracted data were stripped of patient identifiers such as names, home address, and telephone number(s). In addition, the data analysts did not have access to the original data in the EMR and had no way of linking extracted records to any individual patient. Patient serial numbers were, however, maintained for ease of merging datasets from different sources.

### Statistical analysis

Demographic and clinical characteristics that could potentially influence ARV treatment status outcomes were measured at the time of ART initiation, also called "baseline". Descriptive analyses were performed for baseline characteristics. Categorical variables (age group, marital status, residence, care entry point, linkage to ART after HIV diagnosis, WHO stage, CD4 category, OIs and ART start regimen) were summarized using proportions. Continuous variables (age and CD4 count) were summarized using mean values and SDs or medians and interquartile ranges (IQRs) as appropriate. The Cochran--Armitage test for trend was used to determine trends in baseline characteristics over time. All statistical tests were two-sided, and *p*-values \<0.05 were considered significant.

Cox proportional hazards models were used to determine the effect of baseline demographic and clinical characteristics on attrition. Unadjusted and adjusted hazard ratios (aHR) with 95% CIs and *p*-values were generated and used to determine the patient characteristics that were independently associated with ART attrition. Wald confidence limits were used for all Cox univariate/multivariate analyses. Data were analyzed using SAS software 9.2 (SAS Institute, Cary, NC, USA).

Results
=======

A total of 8630 patients were enrolled into care. Of these, 7663 were initiated on ART. After excluding those with a wrong ART start or treatment status outcome date, 7658 were included in the analyses ([Figure 1](#f1-hiv-10-103){ref-type="fig"}).

Patient characteristics at ART initiation
-----------------------------------------

Baseline characteristics are presented in [Table 1](#t1-hiv-10-103){ref-type="table"}. Overall, 63.1% of the patient population was female, 56.1% was married, and 77.6% was urban residents. The mean age at baseline was 38.7 years (SD 9.7), and the most common point of entry into care was the on-site voluntary counseling and testing (VCT) center (42.3%). Thirty-six percent of all patients had an OI at baseline.

Compared to women, men were, at ART initiation, older (41.1 years \[SD 9.5\] vs 37.3 years \[SD 9.5\]), more likely to be married (73.6% vs 45.8%), and had more advanced disease (WHO stage 3 or 4: 43.6% vs 35.2%; CD4 \[median {IQR}\]: 189 \[76--326\] vs 231 \[109--384\]).

Trends in baseline characteristics at ART initiation
----------------------------------------------------

Trends in baseline characteristics stratified by 2-year cohorts are presented in [Table 2A and B](#t2-hiv-10-103){ref-type="table"}. The proportion of older adolescents (15--19 years), youth (20--24 years), and young adults (25--29 years) initiating ART increased during the observation period (*p*=0.0001; [Table 2A](#t2-hiv-10-103){ref-type="table"}). A similar trend was observed among those who were single or divorced (*p*=0.0001). While care entry through the prevention of mother-to-child transmission (PMTCT) and TB clinics declined (*p*=0.0001), the proportion of patients accessing care from the in-patient unit increased (*p*=0.0188). Similarly, care entry following referral from other facilities and other sources increased (*p*=0.0001). Declining trends were noted in the proportions of patients initiated on ART 3 and 6 months after HIV diagnosis (*p*=0.0001; [Table 2B](#t2-hiv-10-103){ref-type="table"}). The proportion of patients initiating ART with CD4 counts \>350 cells/µL increased (*p*=0.0001), while those starting ART with advanced disease (WHO stage 3 or 4) declined over time (*p*=0.0001). Overall, the median CD4 cell count at ART initiation increased ([Figure 2](#f2-hiv-10-103){ref-type="fig"}). The proportion of patients with oral candidiasis at ART initiation declined over time (*p*=0.0001), while that with other OIs or any OI increased (*p*=0.0001; [Table 2B](#t2-hiv-10-103){ref-type="table"}). Overall, nondocumentation of care entry point, disease stage, and CD4 count declined during the period of observation (*p*=0.0001). Nondocumentation of residence, however, increased (*p*=0.0001).

Treatment status outcomes
-------------------------

Overall, at the end of follow-up, 5835 (76.2%) patients were active (on ART), 1501 (19.6%) had either died or were LTFU (attrition), and 322 (4.2%) had transferred out. The median duration on ART was 37 months (IQR 16--83; [Table 3](#t3-hiv-10-103){ref-type="table"}).

### Attrition

Attrition proportions are presented in [Table 4](#t4-hiv-10-103){ref-type="table"}. Overall, ART attrition was higher among males (21.8% \[20.2%--23.3%\]), compared to females; those who were single (21.9% \[20.0%--23.8%\]) or divorced/separated (23.5% \[20.1%--26.9%\]) compared to those who were married; patients entering care from the in-patient (23.4% \[20.2%--26.5%\]) or other facilities (27.1% \[22.0%--32.3%\]), compared to those entering care through the on-site VCT; patients initiating ART in WHO stages 3 and 4 (23.2% \[21.7%--24.7%\]), compared to WHO stages 1 and 2 (16.6% \[15.3%--17.9%\]); and patients with TB at ART initiation (23.4% \[20.5%--26.4%\]) compared to those without TB (19.2% \[18.2%--20.1%\]). Attrition was higher among young patients and declined with increasing age at ART start (adolescents \[15--19 years\] 28.4%, youth \[20--24 years\] 26.4% vs 19.0%--20.2% for patients aged 25 years and older). Patients with missing information on any of the covariates had higher attrition: marital status 20.4% vs 18.4%; residence 24.0% vs 17.3%; care entry point 25.8% vs 18.5%; duration taken to link to ART after HIV diagnosis 22.1% vs 18.2%--18.9%; WHO stage18.8% vs 16.6%; and CD4 count 22.0% vs 17.3%.

aHR for ART attrition are presented in [Table 5](#t5-hiv-10-103){ref-type="table"}. Overall, baseline characteristics that were independently associated with attrition included (aHR \[95% CI\]) male sex: 1.30 (1.16--1.45), *p*=0.0001, compared to female; age: 15--19 years: 1.83 (1.26--2.66), *p*=0.0014; 20--24 years: 1.93 (1.52--2.44), *p*=0.0001; and 25--29 years: 1.31 (1.11--1.54), *p*=0.0012; compared to age 30--54 years; marital status -- single: 1.27 (1.11--1.44), *p*=0.0005; and divorced/separated: 1.56 (1.30--1.87), *p*=0.0001, compared to married; urban residence: 1.40 (1.20--1.64), *p*=0.0001, compared to rural; entry into HIV care from the in-patient: 1.31 (1.10--1.57), *p*=0.0026, and from another facility: 1.60 (1.26--2.04), *p*=0.0001, compared to entry into HIV care from the on-site VCT; initiation of ART \>12 months after the date of HIV diagnosis, and having an OI: 1.15 (1.02--1.30), *p*=0.0284. Nondocumentation of residence, care entry point, and date of HIV diagnosis were also associated with attrition.

Factors that rendered attrition less likely included (aHR \[95% CI\]) entry into care through the TB clinic: 0.79 (0.65--0.96), *p*=0.0192, compared to entry into care through the on-site VCT; and CD4 count 51--100: 0.66 (0.50--0.87), *p*=0.0031, compared to CD4 count 251--350.

Discussion
==========

This study highlights priority areas for focused interventions to improve outcomes in this cohort of patients. The upward trend in ART uptake among adolescents and young people could be an indication of increased awareness and better diagnosis, or that HIV prevention interventions are not reaching these groups in the needed scale. The observed trend is consistent with population-based data reporting increasing incidence[@b15-hiv-10-103] and entry into care and treatment[@b1-hiv-10-103] in this age group. A recent study that followed up youth (15--24 years) in four SSA countries, including Kenya, documented a 4% increase in the proportion initiating ART.[@b16-hiv-10-103] In another analysis, Koech et al found a decrease in the proportion of patients aged 10--14 and 15--19 years, and an increase in the proportion of 20--24-year-old patients initiating ART in Kenya.[@b17-hiv-10-103] A study conducted in Tanzania documented a decline in the proportion of 10--14-year-olds and an increase in the proportion of 15--19- and 20--29-year-olds initiating ART.[@b18-hiv-10-103] Although there are some similar trends, inconsistencies in age cutoffs and varied study settings limit conclusive comparisons.

ART uptake among males was consistently lower than that among females throughout the observation period. They also had lower CD4 counts at ART initiation. This implies that they are seeking care when already in advanced disease, putting them at risk for poor outcomes. This calls for program-level strategies that identify male patients in early stages of disease and link them to treatment.

We observed that the majority of patients entered care through the on-site VCT, suggesting the ongoing demand for these services. This can be attributed to increased awareness of testing that has been achieved through aggressive mass media campaigns countrywide. It will be crucial that the program prioritizes VCT accessibility. HIV programs in Tanzania demonstrated a significant increase in the proportion of patients entering care through the VCT.[@b18-hiv-10-103] Other SSA countries have reported stable[@b19-hiv-10-103] or declining[@b20-hiv-10-103] proportions of patients accessing care and treatment from VCT centers.

Our analysis demonstrated a statistically significant decline in the proportion of patients initiating ART with advanced disease over time, mostly a reflection of changing ART initiation policies, which progressively increased the CD4 count thresholds for ART initiation. This trend could also be a reflection of more referrals from the on-site VCT center, which would typically be attended by healthier patients.[@b18-hiv-10-103],[@b21-hiv-10-103],[@b22-hiv-10-103] Similar trends have been reported in other SSA countries[@b23-hiv-10-103] including Rwanda.[@b24-hiv-10-103]

Overall, median CD4 counts at ART initiation increased over time. The observed upward trend can be explained by the adoption of routine universal testing coupled with revision of national guidelines, which changed ART eligibility from CD4 counts ≤200 cells/mm^3^ to ≤350 cells/µL in 2010[@b25-hiv-10-103] and later to 500 cells/µL in 2014.[@b26-hiv-10-103] The trend is likely to be maintained during the implementation of the most current guidelines that recommend treatment for all HIV-positive clients irrespective of the CD4 count or clinical stage.[@b27-hiv-10-103] Similar trends have been observed in other African countries[@b23-hiv-10-103],[@b24-hiv-10-103] and in Asia.[@b28-hiv-10-103] However, a study in Ethiopia[@b20-hiv-10-103] and a meta-analysis of studies from SSA countries[@b29-hiv-10-103] found that CD4 counts at ART initiation remained stable over time.

There was a progressive increase in enrollment of adolescents, youth, and young adults (15--29 years), single persons, and immunologically healthier clients, all of which are associated with higher attrition. Other factors that were linked to attrition in this setting included male sex, being divorced or separated, care entry through the in-patient, referral from another facility, and history of an OI prior to initiation of ART.

Adolescents and youth face unique challenges in coping with a diagnosis of HIV infection, contributing to the higher attrition observed.[@b16-hiv-10-103],[@b30-hiv-10-103]--[@b32-hiv-10-103] Single persons and those who are separated or divorced may lack social support and hence are unable to adequately deal with the stigma and overall social and economic burden associated with HIV infection. They are, therefore, more prone to attrition.[@b30-hiv-10-103] Consistent with previous work, being male in this cohort was associated with higher risk for attrition.[@b31-hiv-10-103],[@b33-hiv-10-103],[@b34-hiv-10-103]

Referral from a facility other than the study site was predictive of attrition. This being a referral center in a large metropolis, distances, transportation costs, and possibilities of change in employment may be responsible for higher attrition of in-bound referrals.[@b32-hiv-10-103],[@b35-hiv-10-103] Care entry from the inpatient units was independently associated with attrition. These patients are more likely to have advanced disease, hence more prone to mortality associated attrition. Any OI (history of or active) at ART initiation was predictive of attrition. The OIs listed are associated with stage 3 or 4 disease, suggesting that this is most likely mortality-associated attrition.

Contrary to findings of previous research,[@b30-hiv-10-103],[@b31-hiv-10-103],[@b33-hiv-10-103],[@b34-hiv-10-103] our study did not demonstrate that advanced disease (WHO stage 3 and 4) was predictive of mortality-associated attrition. However, this finding should be interpreted with caution because nondocumentation of clinical staging and underreporting of mortality may have contributed to this observation.

TB clinic as a care entry point conferred protection from attrition. Initiating ART prior to enrollment or in the same year of enrollment has been long known to result in improved retention,[@b30-hiv-10-103],[@b34-hiv-10-103] explaining the conferred protection from attrition among patients entering care through the TB clinic.

Strengths of this study include the reasonably large sample size, which rendered sufficient power for precise effect estimates, and the long duration of follow-up, which allowed for trend analysis over time. Limitations of the study are related to the data source. We used routinely collected clinical data, which are more prone to data quality barriers, including missing information, than data specifically collected for research purposes.[@b36-hiv-10-103] The referral nature of KNH renders our study sample highly selective, impacting generalizability of our findings.

Conclusion
==========

Although ART uptake among adolescents and young people increased over time, this group was at increased risk for attrition. Single marital status, urban residence, history of hospitalization or OI, and late initiation of ART also predicted attrition. These findings and current national data underscore the need for policies that call for intensified HIV preventive strategies targeting adolescents and young people, and those that focus on increasing awareness on the availability and importance of HIV counseling and testing services. At program level, there is an urgent need to implement evidence-based interventions that address attrition especially among adolescents, youth, males, and the other at-risk groups highlighted by these data. Finally, these findings reiterate the need to ensure completeness of documentation of health records for all patients.
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###### 

Baseline characteristics

  Baseline characteristics                                                                   Female, n=4831   Male, n=2827    Overall, n=7658
  ------------------------------------------------------------------------------------------ ---------------- --------------- -----------------
  **Age (years)**                                                                                                             
  Mean (SD)                                                                                  37.3 (9.5)       41.1 (9.5)      38.7 (9.7)
  **Age group, n (%), years**                                                                                                 
  15--19                                                                                     60 (1.2)         49 (1.7)        109 (1.4)
  20--24                                                                                     244 (5.1)        52 (1.8)        296 (3.9)
  25--29                                                                                     720 (14.9)       161 (5.7)       881 (11.5)
  30--54                                                                                     3550 (73.5)      2331 (82.5)     5881 (76.8)
  ≥55                                                                                        257 (5.3)        234 (8.3)       491 (6.4)
  **Marital status, n (%)**                                                                                                   
  Single                                                                                     1373 (28.4)      371 (13.1)      1744 (22.8)
  Married                                                                                    2213 (45.8)      2081 (73.6)     4294 (56.1)
  Divorced/separated                                                                         446 (9.2)        145 (5.1)       591 (7.7)
  Widowed                                                                                    619 (12.8)       155 (5.5)       774 (10.1)
  Not documented                                                                             180 (3.7)        75 (2.7)        255 (3.3)
  **Residence, n (%)**                                                                                                        
  Rural                                                                                      696 (14.4)       390 (13.8)      1086 (14.2)
  Urban                                                                                      3684 (76.3)      2262 (80.0)     5946 (77.6)
  Not documented                                                                             451 (9.3)        175 (6.2)       626 (8.2)
  **Year of ART start, n (%)**                                                                                                
  2004--2006                                                                                 708 (14.7)       437 (15.5)      1145 (15.0)
  2007--2008                                                                                 729 (15.1)       397 (14.0)      1126 (14.7)
  2009--2010                                                                                 682 (14.1)       425 (15.0)      1107 (14.5)
  2011--2012                                                                                 1108 (22.9)      695 (24.6)      1803 (23.5)
  2013--2014                                                                                 1211 (25.1)      662 (23.4)      1873 (24.5)
  2015                                                                                       393 (8.1)        211 (7.5)       604 (7.9)
  **Care entry point, n (%)**                                                                                                 
  On-site VCT                                                                                1956 (40.5)      1284 (45.4)     3240 (42.3)
  PMTCT                                                                                      829 (17.2)       366 (12.9)      1195 (15.6)
  TB clinic                                                                                  395 (8.2)        276 (9.8)       671 (8.8)
  In-patient                                                                                 443 (9.2)        259 (9.2)       702 (9.2)
  Other facilities                                                                           180 (3.7)        111 (3.9)       291 (3.8)
  Other sources                                                                              597 (12.4)       322 (11.4)      919 (12.0)
  Not documented                                                                             431 (8.9)        209 (7.4)       640 (8.4)
  **Linkage to ART after HIV diagnosis (time \[months\] from HIV diagnosis to ART start)**                                    
  **Months to linkage**                                                                                                       
  Within 3 months                                                                            1132 (23.4)      811 (28.7)      1943 (25.4)
  Within 6 months                                                                            1362 (28.2)      938 (33.2)      2300 (30.0)
  Within 12 months                                                                           1699 (35.2)      1129 (39.9)     2828 (36.9)
  HIV diagnosis date not documented                                                          1636 (33.9)      898 (31.8)      2534 (33.1)
  Disease stage, n (%)                                                                                                        
  Stages 1 and 2                                                                             2052 (42.5)      1035 (36.6)     3087 (40.3)
  Stages 3 and 4                                                                             1699 (35.2)      1232 (43.6)     2931 (38.3)
  Not documented                                                                             1080 (22.4)      560 (19.8)      1640 (21.4)
  **CD4 count (cells/μL)**                                                                                                    
  Median (IQR)                                                                               231 (109--384)   189 (76--326)   216 (95--359)
  **CD4 category, n (%)**                                                                                                     
  0--50                                                                                      390 (8.1)        331 (11.7)      721 (9.4)
  51--100                                                                                    308 (6.4)        221 (7.8)       529 (6.9)
  101--250                                                                                   909 (18.8)       581 (20.6)      1490 (19.5)
  251--350                                                                                   496 (10.3)       297 (10.5)      793 (10.4)
  351--500                                                                                   427 (8.8)        228 (8.1)       655 (8.6)
  \>500                                                                                      435 (9.0)        160 (5.7)       595 (7.8)
  Not documented                                                                             1866 (38.6)      1009 (35.7)     2875 (37.5)
  **OIs, n (%)**                                                                                                              
  TB                                                                                         410 (8.5)        371 (13.1)      781 (10.2)
  PCP                                                                                        172 (3.6)        99 (3.5)        271 (3.5)
  Cryptococcal disease                                                                       30 (0.6)         21 (0.7)        51 (0.7)
  Oral candidiasis                                                                           153 (3.2)        81 (2.9)        234 (3.1)
  Esophageal candidiasis                                                                     19 (0.4)         8 (0.3)         27 (0.4)
  Kaposi's sarcoma                                                                           42 (0.9)         33 (1.2)        75 (1.0)
  Other OIs[a](#tfn1-hiv-10-103){ref-type="table-fn"}                                        1268 (26.2)      781 (27.6)      2049 (26.8)
  Any OI[b](#tfn2-hiv-10-103){ref-type="table-fn"}                                           1672 (34.6)      1085 (38.4)     2757 (36.0)
  **Start regimen[c](#tfn3-hiv-10-103){ref-type="table-fn"}**, **n (%)**                                                      
  TDF-based regimen                                                                          2274 (49.9)      1337 (50.4)     3611 (50.1)
  AZT-based regimen                                                                          1059 (23.2)      634 (23.9)      1693 (23.5)
  Stavudine-based regimen                                                                    1223 (26.8)      680 (25.7)      1903 (26.4)

**Notes:**

Other OIs: OIs other than those listed in the table.

Any OI: OIs listed in table plus other OIs.

Start regimen: 451 patients (275 females and 176 males) had missing/wrong start regimen.

**Abbreviations:** ART, antiretroviral therapy; AZT, zidovudine; IQR, interquartile range; OI, opportunistic infection; PCP, pneumocystis pneumonia; PMTCT, prevention of mother-to-child transmission; TB, tuberculosis; TDF, tenofovir; VCT, voluntary counseling and testing.

###### 

**(A)** Trends in baseline demographic characteristics by year of ART start

  Baseline characteristics                                                   2004--2006, n=1145       2007--2008, n=1126       2009--2010, n=1107       2011--2012, n=1803       2013--2014, n=1873       2015, n=604       *p*-value
  -------------------------------------------------------------------------- ------------------------ ------------------------ ------------------------ ------------------------ ------------------------ ----------------- ---------------
  **Sex**                                                                                                                                                                                                                   
  Female                                                                     708 (61.8)               729 (64.7)               682 (61.6)               1108 (61.5)              1211 (64.7)              393 (65.1)        0.25
  Male                                                                       437 (38.2)               397 (35.3)               425 (38.4)               695 (38.6)               662 (35.3)               211 (34.9)        Ref
  **Marital status**                                                                                                                                                                                                        
  Single                                                                     230 (20.1)               229 (20.3)               203 (18.3)               407 (22.6)               507 (27.1)               168 (27.8)        **0.0001**
  Married                                                                    684 (59.7)               633 (56.2)               707 (63.9)               1067 (59.2)              906 (48.4)               297 (49.2)        Ref
  Divorced                                                                   70 (6.1)                 83 (7.4)                 62 (5.6)                 105 (5.8)                204 (10.9)               67 (11.1)         **0.0001**
  Widowed                                                                    126 (11.0)               139 (12.3)               106 (9.6)                169 (9.4)                182 (9.7)                52 (8.6)          0.65
  Not documented                                                             35 (3.1)                 42 (3.7)                 29 (2.6)                 55 (3.1)                 74 (4.0)                 20 (3.3)          0.0675
  **Age (years)**                                                                                                                                                                                                           
  15--19                                                                     5 (0.4)                  10 (0.9)                 15 (1.4)                 24 (1.3)                 42 (2.2)                 13 (2.2)          **0.0001**
  20--24                                                                     22 (1.9)                 24 (2.1)                 42 (3.8)                 67 (3.7)                 98 (5.2)                 43 (7.1)          **0.0001**
  25--29                                                                     105 (9.2)                112 (10.0)               130 (11.7)               177 (9.8)                274 (14.6)               83 (13.7)         **0.0001**
  30--54                                                                     949 (82.9)               907 (80.6)               856 (77.3)               1405 (77.9)              1330 (71.0)              434 (71.9)        Ref
  ≥55                                                                        64 (5.6)                 73 (6.5)                 64 (5.8)                 130 (7.2)                129 (6.9)                31 (5.1)          0.0646
  **Residency**                                                                                                                                                                                                             
  Rural                                                                      240 (21.0)               218 (19.4)               181 (16.4)               264 (14.6)               147 (7.9)                36 (6.0)          Ref
  Urban                                                                      820 (71.6)               837 (74.3)               868 (78.4)               1406 (78.0)              1515 (80.9)              500 (82.8)        **0.0001**
  Not documented                                                             85 (7.4)                 71 (6.3)                 58 (5.2)                 133 (7.4)                211 (11.3)               68 (11.3)         **0.0001**
  **Care entry point**                                                                                                                                                                                                      
  VCT                                                                        424 (37.0)               448 (39.8)               497 (44.9)               742 (41.2)               853 (45.5)               276 (45.7)        Ref
  PMTCT                                                                      268 (23.4)               228 (20.3)               194 (17.5)               296 (16.4)               155 (8.3)                54 (8.9)          **0.0001**
  TB clinic                                                                  133 (11.6)               136 (12.1)               132 (11.9)               212 (11.8)               51 (2.7)                 7 (1.2)           **0.0001**
  In-patient                                                                 103 (9.0)                87 (7.7)                 71 (6.4)                 149 (8.3)                209 (11.2)               83 (13.7)         **0.0188**
  Other facilities                                                           28 (2.5)                 25 (2.2)                 25 (2.3)                 65 (3.6)                 138 (7.4)                10 (1.7)          **0.0001**
  Other sources                                                              68 (5.9)                 76 (6.8)                 76 (6.9)                 145 (8.0)                386 (20.6)               168 (27.8)        **0.0001**
  Not documented                                                             121 (10.6)               126 (11.2)               112 (10.1)               194 (10.8)               81 (4.3)                 6 (1.0)           **0.0001**
                                                                                                                                                                                                                            
  (**B**) Trends in baseline clinical characteristics by year of ART start                                                                                                                                                  
  **Baseline characteristics**                                               **2004--2006, n=1145**   **2007--2008, n=1126**   **2009--2010, n=1107**   **2011--2012, n=1803**   **2013--2014, n=1873**   **2015, n=604**   ***p*-value**
                                                                                                                                                                                                                            
  **Time to linkage to ART (months)**                                                                                                                                                                                       
  **3 months**                                                                                                                                                                                                              
  Within 3 months                                                            311 (27.2)               437 (38.8)               345 (31.2)               218 (12.1)               451 (24.1)               181 (30.0)        Ref
  After 3 months                                                             497 (43.4)               342 (30.4)               445 (40.2)               1086 (60.2)              633 (33.8)               178 (29.5)        **0.0001**
  **6 months**                                                                                                                                                                                                              
  Within 6 months                                                            406 (35.5)               484 (43.0)               391 (35.3)               315 (17.5)               509 (27.2)               195 (32.3)        Ref
  After 6 months                                                             402 (35.1)               295 (26.2)               399 (36.0)               989 (54.9)               575 (30.7)               164 (27.2)        **0.0001**
  **12 months**                                                                                                                                                                                                             
  Within 12 months                                                           539 (47.1)               550 (48.9)               472 (42.6)               454 (25.2)               591 (31.6)               222 (36.8)        Ref
  After 12 months                                                            269 (23.5)               229 (20.3)               318 (28.7)               850 (47.1)               493 (26.3)               137 (22.7)        **0.0001**
  **Disease stage**                                                                                                                                                                                                         
  WHO stages 1 and 2                                                         208 (18.2)               380 (33.8)               449 (40.6)               747 (41.4)               924 (49.3)               379 (62.8)        Ref
  WHO stages 3 and 4                                                         441 (38.5)               494 (43.9)               344 (31.1)               833 (46.2)               612 (32.7)               207 (34.3)        **0.0001**
  Not documented                                                             496 (43.3)               252 (22.4)               314 (28.4)               223 (12.4)               337 (18.0)               18 (3.0)          **0.0001**
  **CD4 count**                                                                                                                                                                                                             
  0--50                                                                      105 (9.2)                141 (12.5)               61 (5.5)                 89 (4.9)                 241 (12.9)               84 (13.9)         **0.0001**
  51--100                                                                    92 (8.0)                 122 (10.8)               59 (5.3)                 79 (4.4)                 127 (6.8)                50 (8.3)          **0.0001**
  101--250                                                                   202 (17.6)               277 (24.6)               226 (20.4)               257 (14.3)               391 (20.9)               137 (22.7)        0.24
  251--350                                                                   78 (6.8)                 63 (5.6)                 96 (8.7)                 204 (11.3)               291 (15.5)               61 (10.1)         Ref
  351--500                                                                   33 (2.9)                 48 (4.3)                 46 (4.2)                 197 (10.9)               227 (12.1)               104 (17.2)        **0.0001**
  \>500                                                                      28 (2.5)                 34 (3.0)                 49 (4.4)                 212 (11.8)               186 (9.9)                86 (14.2)         **0.0001**
  Not documented                                                             607 (53.0)               441 (39.2)               570 (51.5)               765 (42.4)               410 (21.9)               82 (13.6)         **0.0001**
  **OIs**                                                                                                                                                                                                                   
  **TB**                                                                                                                                                                                                                    
  No                                                                         1037 (90.6)              1016 (90.2)              1019 (92)                1651 (91.6)              1619 (86.4)              535 (88.6)        Ref
  Yes                                                                        108 (9.4)                110 (9.8)                88 (7.9)                 152 (8.4)                254 (13.6)               69 (11.4)         **0.0007**
  **PCP**                                                                                                                                                                                                                   
  No                                                                         1109 (96.9)              1099 (97.6)              1076 (97.2)              1689 (93.7)              1824 (97.4)              590 (97.7)        Ref
  Yes                                                                        36 (3.1)                 27 (2.4)                 31 (2.8)                 114 (6.3)                49 (2.6)                 14 (2.3)          0.54
  **Cryptococcal disease**                                                                                                                                                                                                  
  No                                                                         1142 (99.7)              1119 (99.4)              1099 (99.3)              1793 (99.5)              1855 (99.0)              599 (99.2)        Ref
  Yes                                                                        3 (0.3)                  7 (0.6)                  8 (0.7)                  10 (0.6)                 18 (1.0)                 5 (0.8)           **0.0489**
  **Oral candidiasis**                                                                                                                                                                                                      
  No                                                                         1081 (94.4)              1083 (96.2)              1085 (98.0)              1756 (97.4)              1832 (97.8)              587 (97.2)        Ref
  Yes                                                                        64 (5.6)                 43 (3.8)                 22 (2.0)                 47 (2.6)                 41 (2.2)                 17 (2.8)          **0.0001**
  **Esophageal candidiasis**                                                                                                                                                                                                
  No                                                                         1140 (99.6)              1121 (99.6)              1105 (99.8)              1798 (99.7)              1866 (99.6)              601 (99.5)        Ref
  Yes                                                                        5 (0.4)                  5 (0.4)                  2 (0.2)                  5 (0.3)                  7 (0.4)                  3 (0.5)           0.91
  **Kaposi's sarcoma**                                                                                                                                                                                                      
  No                                                                         1132 (98.9)              1118 (99.3)              1095 (98.9)              1786 (99.1)              1855 (99.0)              597 (98.8)        Ref
  Yes                                                                        13 (1.1)                 8 (0.7)                  12 (1.1)                 17 (0.9)                 18 (1.0)                 7 (1.2)           0.92
  **Other OIs**                                                                                                                                                                                                             
  No                                                                         948 (82.8)               914 (81.2)               916 (82.8)               1194 (66.2)              1213 (64.8)              424 (70.2)        Ref
  Yes                                                                        197 (17.2)               212 (18.8)               191 (17.3)               609 (33.8)               660 (35.2)               180 (29.8)        **0.0001**
  **Any OI**                                                                                                                                                                                                                
  No                                                                         835 (72.9)               805 (71.5)               809 (73.1)               1027 (57.0)              1038 (55.4)              387 (64.1)        Ref
  Yes                                                                        310 (27.1)               321 (28.5)               298 (26.9)               776 (43.0)               835 (44.6)               217 (35.9)        **0.0001**

**Note:** The *p*-values in bold font are those that met the significance threshold of \<0.05.

**Abbreviations:** ART, antiretroviral therapy; OI, opportunistic infection; PCP, pneumocystis pneumonia; PMTCT, prevention of mother-to-child transmission; Ref, reference; TB, tuberculosis; VCT, voluntary counseling and testing; WHO, World Health Organization.

###### 

Treatment status outcomes at the end of the observation period

  Year of ART start   n          Duration on ART (months) Median (IQR)   Retention % (95% CI)    Attrition % (95% CI)    Transfer out % (95% CI)
  ------------------- ---------- --------------------------------------- ----------------------- ----------------------- -------------------------
  2004--2006          1145       112 (106--119)                          82.9 (80.7--85.1)       13.6 (11.6--15.6)       3.5 (2.4--4.6)
  2007--2008          1126       90 (82--97)                             79.8 (77.4--82.1)       15.9 (13.8--18.0)       4.4 (3.2--5.5)
  2009--2010          1107       66 (59--72)                             75.3 (72.7--77.8)       19.4 (17.1--21.8)       5.3 (4.0--6.7)
  2011--2012          1803       36 (32--37)                             74.0 (72.0--76.1)       21.8 (19.9--23.7)       4.2 (3.2--5.1)
  2013--2014          1873       15 (9--22)                              68.6 (66.4--70.7)       27.3 (25.3--29.4)       4.1 (3.2--5.0)
  2015                604        3 (1--5)                                88.7 (86.2--91.3)       7.8 (5.6--9.9)          3.5 (2.0--4.9)
  **Overall**         **7658**   **37 (16--83)**                         **76.2 (75.2--77.1)**   **19.6 (18.7--20.5)**   **4.2 (3.8--4.6)**

**Note:** The values in bold font reflect the combined treatment status outcomes.

**Abbreviations:** ART, antiretroviral therapy; IQR, interquartile range; Ref, reference.

###### 

Attrition by baseline characteristics

  Baseline characteristics                n      Attrition % (95% CI)
  --------------------------------------- ------ -----------------------
  **Sex**                                        
  Female                                  4831   18.4 (17.3--19.5)^\*^
  Male                                    2827   **21.8 (20.2--23.3)**
  **Age group (years)**                          
  15--19                                  109    28.4 (20.0--36.9)
  20--24                                  296    26.4 (21.3--31.4)
  25--29                                  881    20.2 (17.6--22.9)
  30--54                                  5881   19.0 (18.0--20.0)^\*^
  ≥55                                     491    19.6 (16.0--23.1)
  **Marital status**                             
  Single                                  1744   21.9 (20.0--23.8)
  Married                                 4294   18.4 (17.2--19.5)^\*^
  Divorced/separated                      591    23.5 (20.1--26.9)
  Widowed                                 774    18.2 (15.5--20.9)
  Not documented                          255    20.4 (15.4--25.3)
  **Residence**                                  
  Rural                                   1086   17.3 (15.1--19.6)^\*^
  Urban                                   5946   19.6 (18.6--20.6)
  Not documented                          626    **24.0 (20.6--27.3)**
  **Care entry point**                           
  VCT                                     3240   18.5 (17.2--19.9)^\*^
  PMTCT                                   1195   18.2 (16.0--20.3)
  TB                                      671    17.6 (14.7--20.5)
  In-patient                              702    **23.4 (20.2--26.5)**
  Other facilities                        291    **27.1 (22.0--32.3)**
  Other sources                           919    17.2 (14.8--19.6)
  Not documented                          640    **25.8 (22.4--29.2)**
  **Linked to ART after HIV diagnosis**          
  **3 months**                                   
  Within 3 months                         1943   18.0 (16.3--19.7)^\*^
  After 3 months                          3181   18.6 (17.2--19.9)
  **6 months**                                   
  Within 6 months                         2300   18.6 (17.0--20.2)^\*^
  After 6 months                          2824   18.2 (16.7--19.6)
  **12 months**                                  
  Within 12 months                        2828   17.9 (16.5--19.3)^\*^
  After 12 months                         2296   18.9 (17.3--20.5)
  HIV diagnosis date not documented       2534   22.1 (20.5--23.8)
  **Disease stage**                              
  WHO stages 1 and 2                      3087   16.6 (15.3--17.9)^\*^
  WHO stages 3 and 4                      2931   **23.2 (21.7--24.7)**
  Not documented                          1640   18.8 (16.9--20.7)
  **CD4 count**                                  
  0--50                                   1250   21.8 (19.5--24.0)
  51--100                                 977    19.5 (17.1--22.0)
  101--250                                513    17.0 (13.7--20.2)
  251--350                                793    17.3 (14.6--19.9)^\*^
  351--500                                658    13.7 (11.1--16.3)
  \>500                                   592    15.5 (12.6--18.5)
  Not documented                          2875   **22.0 (20.5--23.5)**
  **OIs**                                        
  **TB**                                         
  No                                      6877   19.2 (18.2--20.1)^\*^
  Yes                                     781    **23.4 (20.5--26.4)**
  **PCP**                                        
  No                                      7387   19.6 (18.7--20.5)^\*^
  Yes                                     271    20.3 (15.5--25.1)
  **Cryptococcal disease**                       
  No                                      7607   19.6 (18.7--20.5)^\*^
  Yes                                     51     15.7 (5.7--25.7)
  **Oral candidiasis**                           
  No                                      7424   19.6 (18.7--20.5)^\*^
  Yes                                     234    20.1 (15.0--25.2)
  **Esophageal candidiasis**                     
  No                                      7631   19.6 (18.7--20.5)^\*^
  Yes                                     27     22.2 (6.5--37.9)
  **Kaposi's sarcoma**                           
  No                                      7583   19.6 (18.7--20.5)^\*^
  Yes                                     75     20.0 (10.9--29.1)
  **Other OIs**                                  
  No                                      5609   19.1 (18.1--20.1)^\*^
  Yes                                     2049   21.0 (19.3--22.8)
  **Any OI**                                     
  No                                      4901   18.9 (17.8--20.0)^\*^
  Yes                                     2757   20.9 (19.4--22.4)

**Notes:** The values in bold font are significant by virtue of the fact that the confidence intervals do not overlap with those of the respective reference categories. Reference categories are indicated by the ^\*^ symbol.

**Abbreviations:** ART, antiretroviral therapy; OI, opportunistic infection; PCP, pneumocystis pneumonia; PMTCT, prevention of mother-to-child transmission; TB, tuberculosis; VCT, voluntary counseling and testing; WHO, World Health Organization.

###### 

Baseline characteristics associated with attrition (death or lost to follow-up) after ART initiation

  Variable                                         HR (95% CI)         *p*-value   aHR (95% CI)            *p*-value
  ------------------------------------------------ ------------------- ----------- ----------------------- ------------
  **Sex**                                                                                                  
  Female                                           Ref                 Ref         Ref                     Ref
  Male                                             1.18 (1.06--1.30)   0.0019      **1.30 (1.16--1.45)**   **0.0001**
  **Age (years)**                                                                                          
  15--19                                           2.17 (1.52--3.11)   0.0001      **1.83 (1.26--2.66)**   **0.0014**
  20--24                                           1.91 (1.52--2.40)   0.0001      **1.93 (1.52--2.44)**   **0.0001**
  25--29                                           1.23 (1.05--1.44)   0.0121      **1.31 (1.11--1.54)**   **0.0012**
  30--54                                           Ref                 Ref         Ref                     Ref
  ≥55                                              1.09 (0.88--1.34)   0.4390      1.13 (0.91--1.39)       0.28
  **Marital status**                                                                                       
  Single                                           1.34 (1.18--1.51)   0.0001      **1.27 (1.11--1.44)**   **0.0005**
  Married                                          Ref                 Ref         Ref                     Ref
  Divorced                                         1.49 (1.24--1.79)   0.0001      **1.56 (1.30--1.87)**   **0.0001**
  Widowed                                          0.97 (0.81--1.16)   0.7423      1.04 (0.86--1.25)       0.69
  Not documented                                   1.16 (0.88--1.53)   0.3030      1.13 (0.85--1.50)       0.42
  **Residency**                                                                                            
  Rural                                            Ref                 Ref         Ref                     Ref
  Urban                                            1.39 (1.19--1.62)   0.0001      **1.40 (1.20--1.64)**   **0.0001**
  Not documented                                   1.82 (1.47--2.25)   0.0001      **1.75 (1.41--2.18)**   **0.0001**
  **Care entry point**                                                                                     
  VCT                                              Ref                 Ref         Ref                     Ref
  PMTCT                                            0.81 (0.69--0.94)   0.0066      0.85 (0.73--1.00)       0.0452
  TB clinic                                        0.78 (0.64--0.95)   0.0153      **0.79 (0.65--0.96)**   **0.0192**
  In-patient                                       1.34 (1.12--1.59)   0.0010      **1.31 (1.10--1.57)**   **0.0026**
  Other facilities                                 1.74 (1.38--2.20)   0.0001      **1.60 (1.26--2.04)**   **0.0001**
  Other sources                                    1.24 (1.04--1.48)   0.0156      1.20 (1.00--1.43)       0.0496
  Not documented                                   1.20 (1.01--1.42)   0.0401      **1.27 (1.06--1.52)**   **0.0091**
  **Time to linkage to ART after HIV diagnosis**                                                           
  Within 12 months                                 Ref                 Ref         Ref                     Ref
  After 12 months                                  1.23 (1.08--1.40)   0.0018      **1.36 (1.19--1.55)**   **0.0001**
  HIV diagnosis date not documented                1.47 (1.30--1.66)   0.0001      **1.48 (1.31--1.67)**   **0.0001**
  **Disease stage**                                                                                        
  WHO stages 1 and 2                               Ref                 Ref         Ref                     Ref
  WHO stages 3 and 4                               1.19 (1.06--1.34)   0.0030      1.10 (0.97--1.25)       0.13
  Not documented                                   0.75 (0.65--0.87)   0.0001      **0.72 (0.62--0.84)**   **0.0001**
  **CD4 cell count (cells/μL)**                                                                            
  0--50                                            1.38 (1.11--1.72)   0.0037      1.18 (0.94--1.48)       0.16
  51--100                                          0.68 (0.52--0.90)   0.0067      **0.66 (0.50--0.87)**   **0.0031**
  101--250                                         0.92 (0.75--1.13)   0.4226      0.92 (0.75--1.13)       0.42
  251--350                                         Ref                 Ref         Ref                     Ref
  351--499                                         0.91 (0.70--1.19)   0.5010      0.84 (0.64--1.09)       0.19
  ≥500                                             1.02 (0.79--1.33)   0.8706      0.89 (0.68--1.16)       0.37
  Not documented                                   0.98 (0.81--1.17)   0.7924      1.04 (0.86--1.26)       0.66
  **OI**                                                                                                   
  **Any OI**                                       1.29 (1.17--1.44)   0.0001      **1.15 (1.02--1.30)**   **0.0284**

**Note:** Values in bold font are statistically significant (*p* \<0.05).

**Abbreviations:** aHR, adjusted hazard ratio; ART, antiretroviral therapy; HR, hazard ratio; OI, opportunistic infection; PMTCT, prevention of mother-to-child transmission; Ref, reference; TB, tuberculosis; VCT, voluntary counseling and testing; WHO, World Health Organization.
